Table 2 Reimbursement relevant key figures (median values)
2016 | 2017 | 2018 | 2019 | 2020† | Total | |
|---|---|---|---|---|---|---|
Length of stay (range) | ||||||
across all G-DRGs | 16 (2–56) | 15 (3–92) | 12.5 (1–34) | 11.5 (2–76) | 12 (5–18) | 13 (1–92) |
ICU treatment (%) | ||||||
across all G-DRGs | 7 (38.9%) | 8 (53.3%) | 7 (35.0%) | 11 (61.1%) | 1 (33.3%) | 34 (46.0%) |
Invasive ventilation (%) | ||||||
across all G-DRGs | 1 (5.6%) | 3 (20.0%) | 2 (10.0%) | 4 (22.2%) | 0 (0.0%) | 10 (13.5%) |
Case-mix index (range) | ||||||
across all G-DRGs | 2.95 (0.76–6.73) | 2.02 (0.78–29.87) | 1.92 (0.33–12.57) | 1.44 (0.33–25.16) | 0.9 (0.68–3.60) | 1.99 (0.33–29.87) |
Secondary diagnosis with reference to renal insufficiency | ||||||
Acute renal failure (N17.-) | 8 | 8 | 10 | 12 | 2 | 40 |
Chronic kidney disease (N18.-) | 10 | 6 | 10 | 7 | 1 | 34 |
Cases per G-DRG (%) | ||||||
across all G-DRGs | 18 (100.0%) | 15 (100.0%) | 20 (100.0%) | 18 (100.0%) | 3 (100.0%) | 74 (100.0%) |
A09B | - | 1 (6.7%) | - | 1 (5.6%) | - | 2 (2.7%) |
A36A | - | - | - | 2 (11.1%) | - | 2 (2.7%) |
R01A | - | 1 (6.7%) | - | - | - | 1 (1.4%) |
R36Z | - | 2 (13.3%) | 1 (5.0%) | - | - | 3 (4.1%) |
R61A | 6 (33.3%) | 1 (6.7%) | 2 (10.0%) | 1 (5.6%) | 1 (33.3%) | 11 (14.9%) |
R61B | 3 (16.7%) | - | 1 (5.0%) | 1 (5.6%) | - | 5 (6.8%) |
R61D | 3 (16.7%) | 3 (20.0%) | 8 (40.0%) | 4 (22.2%) | - | 18 (24.3%) |
R61E | 1 (5.6%) | 2 (13.3%) | - | - | - | 3 (4.1%) |
R61F | - | - | - | 1 (5.6%) | - | 1 (1.4%) |
R61G | - | - | 3 (15.0%) | 2 (11.1% | 1 (33.3%) | 6 (8.1%) |
R61H | 5 (27.8%) | 5 (33.3%) | 4 (20.0%) | 5 (27.8%) | 1 (33.3%) | 20 (27.0%) |
R65B | - | - | 1 (5.0%) | 1 (5.6%) | - | 2 (2.7%) |